Insulet Current Ratio 2010-2025 | PODD
Current and historical current ratio for Insulet (PODD) from 2010 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Insulet current ratio for the three months ending March 31, 2025 was 4.47.
| Insulet Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-03-31 | $2.33B | $0.52B | 4.47 |
| 2024-12-31 | $1.89B | $0.53B | 3.58 |
| 2024-09-30 | $1.86B | $0.51B | 3.68 |
| 2024-06-30 | $1.75B | $0.49B | 3.60 |
| 2024-03-31 | $1.62B | $0.43B | 3.74 |
| 2023-12-31 | $1.58B | $0.45B | 3.51 |
| 2023-09-30 | $1.47B | $0.45B | 3.26 |
| 2023-06-30 | $1.42B | $0.43B | 3.35 |
| 2023-03-31 | $1.33B | $0.38B | 3.47 |
| 2022-12-31 | $1.31B | $0.37B | 3.60 |
| 2022-09-30 | $1.33B | $0.33B | 3.98 |
| 2022-06-30 | $1.31B | $0.28B | 4.69 |
| 2022-03-31 | $1.29B | $0.22B | 5.98 |
| 2021-12-31 | $1.33B | $0.23B | 5.81 |
| 2021-09-30 | $1.31B | $0.23B | 5.72 |
| 2021-06-30 | $1.25B | $0.21B | 5.87 |
| 2021-03-31 | $1.19B | $0.19B | 6.43 |
| 2020-12-31 | $1.25B | $0.21B | 6.01 |
| 2020-09-30 | $1.16B | $0.18B | 6.62 |
| 2020-06-30 | $1.09B | $0.13B | 8.08 |
| 2020-03-31 | $0.54B | $0.13B | 4.15 |
| 2019-12-31 | $0.59B | $0.16B | 3.75 |
| 2019-09-30 | $0.79B | $0.11B | 7.01 |
| 2019-06-30 | $0.50B | $0.11B | 4.72 |
| 2019-03-31 | $0.50B | $0.11B | 4.36 |
| 2018-12-31 | $0.46B | $0.12B | 3.99 |
| 2018-09-30 | $0.45B | $0.10B | 4.58 |
| 2018-06-30 | $0.42B | $0.08B | 5.54 |
| 2018-03-31 | $0.45B | $0.08B | 5.48 |
| 2017-12-31 | $0.54B | $0.09B | 6.24 |
| 2017-09-30 | $0.37B | $0.08B | 4.88 |
| 2017-06-30 | $0.34B | $0.05B | 7.06 |
| 2017-03-31 | $0.34B | $0.04B | 8.56 |
| 2016-12-31 | $0.37B | $0.06B | 6.64 |
| 2016-09-30 | $0.36B | $0.05B | 6.67 |
| 2016-06-30 | $0.18B | $0.06B | 3.29 |
| 2016-03-31 | $0.17B | $0.05B | 3.45 |
| 2015-12-31 | $0.19B | $0.07B | 2.93 |
| 2015-09-30 | $0.19B | $0.06B | 3.27 |
| 2015-06-30 | $0.20B | $0.05B | 3.87 |
| 2015-03-31 | $0.21B | $0.05B | 4.34 |
| 2014-12-31 | $0.21B | $0.04B | 4.70 |
| 2014-09-30 | $0.21B | $0.05B | 4.33 |
| 2014-06-30 | $0.23B | $0.07B | 3.26 |
| 2014-03-31 | $0.20B | $0.04B | 4.64 |
| 2013-12-31 | $0.20B | $0.04B | 4.68 |
| 2013-09-30 | $0.20B | $0.05B | 4.14 |
| 2013-06-30 | $0.20B | $0.03B | 5.82 |
| 2013-03-31 | $0.20B | $0.04B | 4.53 |
| 2012-12-31 | $0.11B | $0.05B | 2.28 |
| 2012-09-30 | $0.11B | $0.05B | 2.32 |
| 2012-06-30 | $0.12B | $0.04B | 2.70 |
| 2012-03-31 | $0.13B | $0.03B | 3.94 |
| 2011-12-31 | $0.13B | $0.03B | 4.74 |
| 2011-09-30 | $0.14B | $0.03B | 5.57 |
| 2011-06-30 | $0.15B | $0.03B | 5.56 |
| 2011-03-31 | $0.13B | $0.02B | 7.95 |
| 2010-12-31 | $0.14B | $0.02B | 7.52 |
| 2010-09-30 | $0.13B | $0.02B | 6.52 |
| 2010-06-30 | $0.15B | $0.02B | 6.13 |
| 2010-03-31 | $0.14B | $0.02B | 7.93 |
| 2009-12-31 | $0.15B | $0.02B | 7.79 |
| 2009-09-30 | $0.10B | $0.02B | 5.48 |
| 2009-06-30 | $0.08B | $0.02B | 4.79 |
| 2009-03-31 | $0.10B | $0.02B | 5.05 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $22.464B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $231.329B | 27.82 |
| Boston Scientific (BSX) | United States | $151.540B | 37.94 |
| Stryker (SYK) | United States | $146.015B | 30.53 |
| EssilorLuxottica (ESLOY) | France | $127.709B | 0.00 |
| Medtronic (MDT) | Ireland | $109.786B | 15.56 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.554B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.214B | 28.03 |
| ResMed (RMD) | United States | $36.648B | 27.53 |
| Agilent Technologies (A) | United States | $32.650B | 21.28 |
| GE HealthCare Technologies (GEHC) | United States | $32.569B | 15.46 |
| Terumo (TRUMY) | Japan | $26.857B | 34.88 |
| Koninklijke Philips (PHG) | Netherlands | $21.600B | 15.53 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.095B | 11.62 |
| Baxter (BAX) | United States | $15.380B | 11.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.819B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.637B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.043B | 21.03 |
| Lantheus Holdings (LNTH) | United States | $5.509B | 13.90 |
| Prestige Consumer Healthcare (PBH) | United States | $4.190B | 18.72 |
| Perrigo (PRGO) | Ireland | $3.610B | 9.15 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.346B | 15.24 |
| ICU Medical (ICUI) | United States | $3.233B | 23.84 |
| Envista Holdings (NVST) | United States | $3.178B | 26.41 |
| GN Store Nord (GNNDY) | Denmark | $2.155B | 17.85 |
| QuidelOrtho (QDEL) | United States | $2.102B | 14.46 |
| LeMaitre Vascular (LMAT) | United States | $1.865B | 41.69 |
| AtriCure (ATRC) | United States | $1.729B | 0.00 |
| Acuren (TIC) | United States | $1.228B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.196B | 12.14 |
| Green Thumb Industries (GTBIF) | United States | $1.101B | 24.76 |
| Neogen (NEOG) | United States | $1.077B | 13.78 |
| BioLife Solutions (BLFS) | United States | $1.046B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.016B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.972B | 12.42 |
| InMode (INMD) | Israel | $0.931B | 9.38 |
| Evolus (EOLS) | United States | $0.632B | 0.00 |
| CeriBell (CBLL) | United States | $0.619B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.571B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.564B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.563B | 0.00 |
| Valneva SE (VALN) | France | $0.523B | 0.00 |
| Owens & Minor (OMI) | United States | $0.515B | 4.27 |
| Surmodics (SRDX) | United States | $0.429B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.412B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.340B | 12.52 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.313B | 55.70 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.275B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| Sanara MedTech (SMTI) | United States | $0.260B | 0.00 |
| ZimVie (ZIMV) | United States | $0.255B | 11.61 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.231B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.217B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.205B | 0.00 |
| Brainsway (BWAY) | Israel | $0.198B | 52.30 |
| Omeros (OMER) | United States | $0.196B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.195B | 0.00 |
| Biote (BTMD) | United States | $0.194B | 5.45 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.80 |
| Organigram Global (OGI) | Canada | $0.179B | 0.00 |
| Exagen (XGN) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.136B | 16.72 |
| Vireo Growth (VREOF) | United States | $0.125B | 0.00 |
| Jin Medical (ZJYL) | China | $0.121B | 0.00 |
| Veru (VERU) | United States | $0.096B | 0.00 |
| MacroGenics (MGNX) | United States | $0.095B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.56 |
| TerrAscend (TSNDF) | Canada | $0.089B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Zynex (ZYXI) | United States | $0.065B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.02 |
| Nephros (NEPH) | United States | $0.035B | 47.43 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.021B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |